News Articles

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and... INGELHEIM, Germany -Thursday 27 July 2017

First patient enrolled into VOLTAIRE-X; an interchangeability study designed to assess whether BI 695501 is interchangeable with Humira®1 First study in the U.S. to investigate an interchangeability designation for an adalimumab biosimilar candidate BI 695501 is currently under review by...

People with idiopathic pulmonary fibrosis (IPF) reveal high burden of disease in new survey  -Monday 24 July 2017

• 61% of IPF patients are worried or extremely worried about experiencing an acute IPF exacerbation1 • Survey underlines the importance of appropriate support and coping mechanisms for patients living with IPF1 • Healthcare teams emphasise the need of a strong support network and...

Final Phase III Study Results Confirm Benefit of Praxbind® as Reversal Agent for Pradaxa®... -Tuesday 11 July 2017  

Complete data set from 503 patients show that Praxbind® (idarucizumab) led to immediate, complete and sustained reversal of the anticoagulant effect of Pradaxa® (dabigatran etexilate) in emergency settings1 Final results from RE-VERSE AD™ were presented as a late-breaker at the ISTH...

New data reveal high rates of stroke history in asymptomatic atrial fibrillation patients -Wednesday 21 June 2017  

Findings from global observational study, GLORIA™-AF, reinforce the high need for screening programmes1 Data presented at EHRA-EUROPACE CARDIOSTIM 2017 and selected for Highlights Session (abstract 1669)1 (BUSINESS WIRE)-- Boehringer Ingelheim today announced findings from...

Encouraging Phase II survival data for nintedanib in malignant pleural mesothelioma presented at ASCO 2017 -Monday 5 June 2017

(BUSINESS WIRE)-- Boehringer Ingelheim today announced that Phase II results from LUME-Meso, a randomised, double-blind, placebo-controlled trial, have been presented as part of an Oral Abstract Session at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO). Nintedanib*,...

Boehringer Ingelheim: A New World Leader in Animal Health -Wednesday 5 April 2017

(BUSINESS WIRE)-- Three months after acquiring animal health leader Merial in a strategic transaction with Sanofi, Boehringer Ingelheim revealed its ambition to compete for industry leadership worldwide in animal health. Boehringer Ingelheim management discussed the importance of its animal...

First dedicated outcome trials of empagliflozin in chronic heart failure initiated -Friday 17 March 2017  

EMPEROR HF clinical trial programme will evaluate the efficacy and safety of empagliflozin in patients with chronic heart failure, including those with and without type 2 diabetes Heart failure (HF) affects 26 million people worldwide and is associated with high morbidity and...

Jardiance® (empagliflozin) becomes first type 2 diabetes medicine in the EU to include cardiovascular... -Thursday 26 January 2017  

This is the first time the European Commission approved the use of a diabetes treatment for its effect on both blood sugar control and cardiovascular (CV) events The CV data incorporated into the updated label are from the EMPA-REG OUTCOME® trial, which showed Jardiance® reduced the risk...

Sanofi and Boehringer Ingelheim Confirm Closing of Business Swap on January 1st 2017 -Monday 2 January 2017  

(BUSINESS WIRE)-- Sanofi and Boehringer Ingelheim confirmed today that the strategic transaction signed in June 2016, which consists of an exchange of Sanofi’s animal health business (Merial) and Boehringer Ingelheim’s consumer healthcare (CHC) business, has been successfully closed in...

CHMP adopts a positive opinion acknowledging that Jardiance® reduces the risk of CV death -Friday 16 December 2016  

In the EMPA-REG OUTCOME® trial Jardiance® reduced the risk of cardiovascular (CV) death by 38 percent vs placebo in patients with type 2 diabetes (T2D) and established CV disease when added to standard of care The Committee for Medicinal Products for Human Use (CHMP) recommends to...

New Data Show High Adherence Rates with Pradaxa® (dabigatran etexilate) in NVAF Patients -Monday 5 December 2016  

New analysis of GLORIA™-AF Registry Program includes data from nearly 3,000 patients across the world1 Data presented at the American Society of Hematology (ASH) Annual Meeting1 (BUSINESS WIRE)-- Boehringer Ingelheim today announced results from a new analysis of the...

Boehringer Ingelheim and China Southeast University collaborate to develop new treatment approaches for hearing loss -Monday 28 November 2016  

  360 million people worldwide suffer from disabling hearing loss with no effective treatment available New collaboration with China Southeast University is part of the Research Beyond Borders (RBB) initiative, which aims to explore emerging science within and beyond Boehringer...

Jardiance® (empagliflozin) consistently reduced the risk of cardiovascular death in adults with type 2 diabetes... -Monday 14 November 2016  

(BUSINESS WIRE)-- New data presented at the American Heart Association Scientific Sessions 2016 showed that Jardiance® (empagliflozin) consistently reduced the risk for cardiovascular death, regardless of the type of cardiovascular disease at baseline, compared with placebo when added to...

Boehringer Ingelheim’s adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in... -Wednesday 26 October 2016

Phase III study established equivalence in efficacy and similar safety profile between BI 695501 and Humira® (adalimumab) in patients with active rheumatoid arthritis (RA) Results pave the way for submitting BI 695501 for regulatory approval in key markets (BUSINESS WIRE)--...

Boehringer Ingelheim and Sarah Cannon Research Institute launch strategic collaboration to develop novel immune-oncology... -Thursday 29 September 2016  

(BUSINESS WIRE)-- Boehringer Ingelheim and Sarah Cannon Research Institute, the research arm of Sarah Cannon, the global cancer institute of HCA, announced today a new strategic collaboration. This partnership brings together Boehringer Ingelheim’s extensive experience in cancer drug...

New survey reveals 9 out of 10 patients with IPF were happy with how their doctor told them about their IPF diagnosis -Tuesday 20 September 2016  

However, need for additional information to help patients at IPF diagnosis identified Survey also revealed that physicians’ understanding of their patients’ priorities were aligned with patients' actual priorities at diagnosis (BUSINESS WIRE)-- A diagnosis of IPF is news...

Glyxambi® (empagliflozin/linagliptin) approval recommended by CHMP for adults with type 2 diabetes in the European... -Saturday 17 September 2016  

(BUSINESS WIRE)-- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) today recommended the approval of Glyxambi® (empagliflozin/linagliptin) for use in adults with type 2 diabetes (T2D). Glyxambi®, from the Boehringer Ingelheim and Eli Lilly and...

New long-term data demonstrates continued safety and beneficial effect of OFEV® (nintedanib) for patients with IPF -Wednesday 7 September 2016

Interim data suggest long-term benefit with consistent yearly changes in forced vital capacity up to 3 years in patients treated with OFEV® in INPULSIS® and INPULSIS®-ON Long-term treatment up to 51 months had a manageable safety and tolerability profile, with no new safety signals...

Boehringer Ingelheim launches RE-VECTO global program to capture data on Praxbind® usage in clinical practice -Monday 15 August 2016  

Praxbind® (idarucizumab) is the specific reversal agent for the oral anticoagulant Pradaxa® (dabigatran)1,2 Praxbind® is already available in over 5,000 hospitals worldwide and is approved in over 35 countries3 RE-VECTO will provide insights into the diverse types of situations in...

Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer -Wednesday 13 July 2016

• Study to evaluate potential of novel combination therapy for hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC) • Boehringer Ingelheim’s IGF mAB BI 836845 and Lilly’s CDK 4 and 6 inhibitor abemaciclib have shown...

Results 41-60 of 71